From the University/British Heart Foundation Centre for Cardiovascular Science, The University of Edinburgh, Scotland, United Kingdom (N.K.J., K.S., A.C., R.I.M., A.T., C.M.M., C.C., B.R.C., L.D., D.E.W.L., P.W.H., D.J.W., N.D., J.W.D., J.J.M., M.A.B.).
Discovery Sciences, IMED Biotech Unit, AstraZeneca R&D Gothenburg, Sweden (J.W.).
Hypertension. 2020 May;75(5):1213-1222. doi: 10.1161/HYPERTENSIONAHA.119.14308. Epub 2020 Mar 23.
GPR81 (G-protein-coupled receptor 81) is highly expressed in adipocytes, and activation by the endogenous ligand lactate inhibits lipolysis. GPR81 is also expressed in the heart, liver, and kidney, but roles in nonadipose tissues are poorly defined. GPR81 agonists, developed to improve blood lipid profile, might also provide insights into GPR81 physiology. Here, we assessed the blood pressure and renal hemodynamic responses to the GPR81 agonist, AZ'5538. In male wild-type mice, intravenous AZ'5538 infusion caused a rapid and sustained increase in systolic and diastolic blood pressure. Renal artery blood flow, intrarenal tissue perfusion, and glomerular filtration rate were all significantly reduced. AZ'5538 had no effect on blood pressure or renal hemodynamics in mice. mRNA was expressed in renal artery vascular smooth muscle, in the afferent arteriole, in glomerular and medullary perivascular cells, and in pericyte-like cells isolated from kidney. Intravenous AZ'5538 increased plasma ET-1 (endothelin 1), and pretreatment with BQ123 (endothelin-A receptor antagonist) prevented the pressor effects of GPR81 activation, whereas BQ788 (endothelin-B receptor antagonist) did not. Renal ischemia-reperfusion injury, which increases renal extracellular lactate, increased the renal expression of genes encoding ET-1, KIM-1 (Kidney Injury Molecule 1), collagen type 1-α1, TNF-α (tumor necrosis factor-α), and F4/80 in wild-type mice but not in mice. In summary, activation of GPR81 in vascular smooth muscle and perivascular cells regulates renal hemodynamics, mediated by release of the potent vasoconstrictor ET-1. This suggests that lactate may be a paracrine regulator of renal blood flow, particularly relevant when extracellular lactate is high as occurs during ischemic renal disease.
GPR81(G 蛋白偶联受体 81)在脂肪细胞中高度表达,其内源性配体乳酸盐的激活可抑制脂肪分解。GPR81 在心脏、肝脏和肾脏中也有表达,但在非脂肪组织中的作用尚未明确。开发用于改善血脂谱的 GPR81 激动剂,也可能为 GPR81 生理学提供新的见解。在此,我们评估了 GPR81 激动剂 AZ'5538 对血压和肾脏血流动力学的影响。在雄性野生型小鼠中,静脉内输注 AZ'5538 可迅速且持续地增加收缩压和舒张压。肾动脉血流、肾内组织灌注和肾小球滤过率均显著降低。在 GPR81 基因敲除小鼠中,AZ'5538 对血压或肾脏血流动力学没有影响。GPR81 mRNA 表达于肾动脉血管平滑肌、入球小动脉、肾小球和髓质血管周围细胞以及从肾脏分离出的周细胞样细胞中。静脉内给予 AZ'5538 可增加血浆内皮素 1(ET-1)水平,而预先给予 BQ123(内皮素 A 受体拮抗剂)可预防 GPR81 激活的升压作用,而 BQ788(内皮素 B 受体拮抗剂)则没有。肾缺血再灌注损伤会增加肾脏细胞外乳酸盐的含量,从而增加野生型小鼠肾脏中编码 ET-1、KIM-1(肾损伤分子 1)、胶原 1-α1、TNF-α(肿瘤坏死因子-α)和 F4/80 的基因表达,但在 GPR81 基因敲除小鼠中则没有。总之,血管平滑肌和血管周围细胞中的 GPR81 激活通过释放强效血管收缩剂 ET-1 来调节肾脏血流动力学。这表明乳酸盐可能是一种旁分泌调节因子,对肾血流量起调节作用,尤其是在细胞外乳酸盐含量较高时,例如发生缺血性肾病时。